Typically, the Food, Drug, and Cosmetic Act prohibits compounding drugs that are just copies of commercially available medications
On the positive side, GLP1-S has demonstrated cardiovascular benefits in large outcome trials, with evidence suggesting a reduction in the risk of major adverse cardiovascular events in participants with type 2 diabetes
Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis
(2024) examined 9,465 patients with type 2 diabetes undergoing THA, comparing 1,653 semaglutide users to a matched control group of 7,812 non-users
Each material type offers specific advantages regarding biocompatibility, drug-loading capacity, degradation profiles, and routes of administration
Transfers to the United States only take place where recipients are certified under the EUUS Data Privacy Framework or where Standard Contractual Clauses have been implemented